nach oben

Erschienen in:

01.06.2007

Oral Administration of Candesartan Improves the Survival of Mice with Viral Myocarditis through Modification of Cardiac Adiponectin Expression

verfasst von: Seiichiro Saegusa, Yu Fei, Takashi Takahashi, Hiroyuki Sumino, Junji Moriya, Ken Kawaura, Jun-ichi Yamakawa, Tohoru Itoh, Shigeto Morimoto, Takeshi Nakahashi, Kunimitsu Iwai, Masayuki Matsumoto, Tsugiyasu Kanda

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We examined the effects of the angiotensin II receptor type1 blocker candesartan on myocarditis injury in a murine model of acute myocarditis. We hypothesized that candesartan improves cardiac damage by inducing cardiac expression of adiponectin.

Methods and results

We examined changes in heart failure caused by myocarditis in mice by candesartan based on induction of cardiac adiponectin expression. We intraperitoneally injected encephalomyocarditis virus in C3H mice, then orally administered candesartan (10 mg/kg/day) or vehicle (control). The 7 day survival rate was 18% in the control group, but 60% in the candesartan group. The heart weight/body weight ratio in the candesartan group was significantly lower than in the control group. Circulating adiponectin concentrations on day 7 were significantly higher in the candesartan group compared with the control group (7.91 ± 0.61 vs. 6.04 ± 2.26 μg/ml, P < 0.05). Comparative expression of cardiac adiponectin mRNA in the candesartan group was significantly higher than in the control group on day 7 (55.4 ± 41.3 vs. 5.3 ± 7.7, P < 0.05). Immunohistochemical staining and in situ hybridization showed that cardiac expression of adiponectin protein and mRNA was present in the candesartan group on day 7.

Conclusion

Oral administration of candesartan improves survival and decreases myocardial damage in mice with viral myocarditits and induces expression of cardiac adiponectin. The induction of adiponectin might provide cardioprotective effects against acute heart failure due to viral myocarditis.

Nimata M, Kishimoto C, Yuan Z, Shioji K. Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis. Mol Cell Biochem 2004;259:217–22.PubMedCrossRef

Kanda T, McManus JE, Yang DC, McManus BM, Imai S, Suzuki T, et al. Modification of viral myocarditis in mice by interleukin-6. Circ Res 1996;78:848–58.PubMed

Araki M, Kanda T, Imai S, Suzuki T, Murata K, Kobayashi I. Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus. J Cardiovasc Pharmacol 1995;26:61–5.PubMedCrossRef

Shirai K, Watanabe K, Ma M, Wahed MI, Inoue M, Saito Y, et al. Effects of angiotensin-II receptor blocker candesartan cilexetil in rats with dilated cardiomyopathy. Mol Cell Biochem 2005;269:137–42.PubMedCrossRef

Wu L, Iwai M, Nakagami H, Li Z, Chen R, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2001;104:2716–21.PubMed

Lorenzo O, Ruiz-Ortega M, Suzuki Y, Ruperez M, Esteban V, Sugaya T, et al. Angiotensin III activates nuclear transcription factor-kappaB in cultured mesangial cells mainly via AT(2) receptors: studies with AT(1) receptor-knockout mice. J Am Soc Nephrol 2002;13:1162–71.PubMedCrossRef

Berthonneche C, Sulpice T, Tanguy S, O’Connor S, Herbert JM, Janiak P, et al. AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats. Cardiovasc Drugs Ther 2005;19:251–9.PubMedCrossRef

Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296–301.PubMed

Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75.PubMedCrossRef

10.

Yamamoto K, Shioi T, Uchiyama K, Miyamoto T, Sasayama S, Matsumori A. Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice. J Am Coll Cardiol 2003;42:2000–6.PubMedCrossRef

11.

Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, Kusaka K, et al. Angiotensin-II receptor antagonist alleviates non-alcoholic fatty liver in KKAy obese mice with type 2 diabetes. J Int Med Res 2006;34:297–302.PubMed

12.

Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, et al. Long-term angiotensin II AT(1) receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 2006;552:112–22.PubMedCrossRef

13.

Takahashi T, Saegusa S, Sumino H, Nakahashi T, Iwai K, Morimoto S, et al. Adiponectin, T-cadherin and tumor necrosis factor-alpha in damaged cardiomyocytes from autopsy specimens. J Int Med Res 2005;33:236–44.PubMed

14.

Takahashi T, Yu F, Saegusa S, Sumino H, Nakahashi T, Iwai K, et al. Impaired expression of cardiac adiponectin in leptin-deficient mice with viral myocarditis. Int Heart J 2006;47:107–23.PubMedCrossRef

15.

Ishikawa Y, Akasaka Y, Ishii T, Yoda-Murakami M, Choi-Miura NH, Tomita M, et al. Changes in the distribution pattern of gelatin-binding protein of 28 kDa (adiponectin) in myocardial remodelling after ischaemic injury. Histopathology 2003;42:43–52.PubMedCrossRef

16.

Tanaka A, Matsumori A, Wang W, Sasayama S. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation 1994;90:2051–55.PubMed

17.

Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29–33.PubMedCrossRef

18.

Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76–81.PubMedCrossRef

19.

Kapadia SR, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997;81:187–95.PubMed

20.

Sun M, Dawood F, Wen WH, Chen M, Dixon I, Kirshenbaum LA, et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial ruptureand left ventricular dysfunction. Circulation 2004;110:3221–8.PubMedCrossRef

21.

Yue P, Massie BM, Simpson PC, Long CS. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol 1998;275:H250–8PubMed

22.

Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993;92:2303–2312.PubMedCrossRef

23.

Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731–7.PubMedCrossRef

24.

Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S, et al. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003;285:E1072–80.PubMed

Titel: Oral Administration of Candesartan Improves the Survival of Mice with Viral Myocarditis through Modification of Cardiac Adiponectin Expression
verfasst von: Seiichiro Saegusa
Yu Fei
Takashi Takahashi
Hiroyuki Sumino
Junji Moriya
Ken Kawaura
Jun-ichi Yamakawa
Tohoru Itoh
Shigeto Morimoto
Takeshi Nakahashi
Kunimitsu Iwai
Masayuki Matsumoto
Tsugiyasu Kanda
Publikationsdatum: 01.06.2007
Verlag: Kluwer Academic Publishers-Plenum Publishers
Erschienen in: Cardiovascular Drugs and Therapy / Ausgabe 3/2007
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-007-6024-4

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Oral Administration of Candesartan Improves the Survival of Mice with Viral Myocarditis through Modification of Cardiac Adiponectin Expression